SCHEMBL6724008

SCHEMBL6724008

O=C(Nc1cccc(Cl)c1)C(c1ccccc1)N(S)C(=O)Nc1ccccc1C(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.54
GRIK1 P39086 1/20 0.47
CASR P41180 2/20 0.45
ALDH1A1 P00352 5/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
GAA P10253 1/20 0.45
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
KDM4E B2RXH2 2/20 0.42
EPHX2 P34913 1/20 0.41
MAPT P10636 5/20 0.41
HPGD P15428 1/20 0.41
LMNA P02545 3/20 0.41
MEN1 O00255 3/20 0.41
HTT P42858 2/20 0.41
ALPL P05186 1/20 0.40
ALPI P09923 1/20 0.40
ALPG P10696 1/20 0.40
ALOX12 P18054 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6717581 0.89 GRIK1 (0.47) KMT2AGRIK1CASRALDH1A1SMN1; SMN2
SCHEMBL6717048 0.87 GRIK1 (0.48) KMT2AGRIK1ALDH1A1SMN1; SMN2GAA
SCHEMBL6714154 0.85 CASR (0.47) KMT2AGRIK1CASRALDH1A1SMN1; SMN2
SCHEMBL6715754 0.81 MAPT (0.46) KMT2AALDH1A1NPC1RAB9AKDM4E
SCHEMBL6717165 0.81 MAPT (0.54) KMT2ACASRALDH1A1SMN1; SMN2GAA
SCHEMBL6715503 0.81 POLB (0.44) KMT2AALDH1A1NPC1RAB9AKDM4E
SCHEMBL6716817 0.81 POLB (0.42) KMT2AALDH1A1NPC1RAB9AKDM4E
SCHEMBL6714006 0.79 ALDH1A1 (0.45) KMT2AALDH1A1SMN1; SMN2GAANPC1
SCHEMBL6717563 0.79 POLB (0.43) KMT2AALDH1A1SMN1; SMN2GAANPC1
SCHEMBL6724004 0.79 KMT2A (0.67) KMT2AGRIK1CASRALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 KMT2A 2020/4885GRIK1 121/4885CASR 2881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.